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BACKGROUND: Slow-flow superficial vascular malformations (VMs) are rare
congenital anomalies that can be responsible for pain and functional impairment.
Currently, we have no guidelines for their management, which can involve physical
bandages, sclerotherapy, surgery, anti-inflammatory or anti-coagulation drugs or no
treatment. The natural history is progressive and worsening. Mammalian target of
rapamycin (mTOR) is a serine/threonine kinase that acts as a master switch in cell
proliferation, apoptosis, metabolism and angio/lymphangiogenesis. Sirolimus directly
inhibits the mTOR pathway, thereby inhibiting cell proliferation and
angio/lymphangiogenesis. Case reports and series have reported successful use of
sirolimus in children with different types of vascular anomalies, with heterogeneous
outcomes.
OBJECTIVE: The objective of this trial is to evaluate the efficacy and safety of sirolimus
in children with complicated superficial slow-flow VMs.
METHODS/DESIGN: This French multicenter randomized observational-phase, phase
2 trial aims to include 50 pediatric patients 6 to 18 years old who have slow-flow
(lymphatic, venous or lymphatico-venous) voluminous complicated superficial VM.
Patients will be followed up for 12 months. All patients will start with an observational
period (no treatment). Then at a time randomly selected between month 4 and month
8, they will switch to the experimental period (switch time), when they will receive
sirolimus until month 12. Each child will undergo MRI 3 times: at baseline, at the
switch time, and at month 12. For both periods (observational and treatment), we will
calculate the relative change in volume of the VM divided by the study period duration.
This relative change weighted by the study period duration will constitute the primary
endpoint. VM will be measured by MRI images, which will be centralized and
interpreted by the same radiologist who will be blinded to the study period. Hence,
each patient will be his/her own control. Secondary outcomes will include assessment
of safety and efficacy by viewing standardized digital photographs and according to
the physician, the patient or proxy; impact on quality of life; and evolution of biological
makers (coagulation factors, vascular endothelial growth factor, tissue factor).
DISCUSSION: The main benefit of the study will be to resolve uncertainty concerning
the efficacy of sirolimus in reducing the volume of VMs and limiting related
complications and the safety of the drug in children with slow-flow VMs. This trial
design is interesting in these rare conditions because all included patients will have
the opportunity to receive the drug and the physician can maintain it after the end of
the protocol if is found efficient (which would not be the case in a classical cross-over
study).
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02509468 , first received: 28
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